Advertisement

The Radioiodine Treatment of Thyroid Cancer

  • David V. Becker
Chapter
Part of the Handbuch der Medizinischen Radiologie / Encyclopedia of Medical Radiology book series (HDBRADIOL, volume 15 / 2)

Abstract

A rare disease with a natural history of very long duration and a very high survival rate poses particularly difficult problems in terms of the appraisal of any modality of therapy. It is hardly surprising that in the treatment of thyroid cancer, enormously different results have been reported from many different competent centers. The rarity of the disease permits only the largest centers to accumulate sufficient patients to allow any type of statistical analysis. Even then, local medical situations bring patients to these centers at greatly varying stages and severity of disease, providing enormous preselection of patient populations and significant inherent bias. This ranges from centers that receive patients primarily with small newly discovered nodules to those that primarily see patients with large long standing and progressively growing neck masses. Pathologic classification too, differs from center to center and even from pathologist to pathologist, to say nothing of international differences. This inevitably influences the selection and classification of patients that constitute each published series.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barandes, M., Hurley, J.R., Becker, D.V.: Implications of rapid intrathyroidal iodine turnover for 131I therapy; the small pool syndrome. J. nucl. Med. 14, 379 (1973) Abstract.Google Scholar
  2. Benua, R.S., Cicale, N.R., Sonenberg, M., Raw-Son, R.W.: The Relation of Radioiodine Dosimetry to Results and Complications in the Treatment of Metastatic Thyroid Cancer. Amer. J. Roentgenol. 87, 171–182 (1962).PubMedGoogle Scholar
  3. Brincker, H., Hansen, H.S., Andersen, A.P.: Induction of leukemia by 131I treatment of thyroid carcinoma. Brit. J. Cancer 28, 232–237 (1973).PubMedCrossRefGoogle Scholar
  4. Decosse, J.J., Beierwaltes, W.H., Brooks, J.R., Thomas, C.G., Woolner, L.B.: Carcinoma of the Thyroid. Arch. Surg. 110, 783–789 (1975).CrossRefGoogle Scholar
  5. Edmonds, C.J., Smith, T., Barnaby, C.F.: Follow-up of Thyroid Carcinoma by Whole-body Counting. Brit. J. Radiol. 43, 868–75 (1970).PubMedCrossRefGoogle Scholar
  6. Greene, R.: Treatment of Thyroid Cancer. Brit. med. J. 4, 787–789 (1969).Google Scholar
  7. Hamburger, J.I.: Diuretic Augmentation of 131I Uptake in Inoperable Thyroid Cancer. New Engl. J. Med.: 280, 1091–4 (1969).Google Scholar
  8. Henk, J.M., Kirkman, S., Owen, G.M.: Whole-body Scanning and 131I Therapy in the Management of Thyroid Carcinoma. Brit. J. Radiol. 45, 369–376 (1972).PubMedCrossRefGoogle Scholar
  9. Hurley, J.R., Becker, D.V.: Preliminary Communication, (1975).Google Scholar
  10. Kyriakides, G., Sosin, H.: Anaplastic Carcinoma of the Thyroid. Ann. Surg. 179, 295–299 (1974).PubMedCrossRefGoogle Scholar
  11. Leeper, R.D.: The Effect of 131I Therapy on Survival of Patients with Metastatic Papillary or Follicular Thyroid Carcinoma. J. clin. Endocr. 36, 1143–1152 (1973).PubMedCrossRefGoogle Scholar
  12. Lindahl, F.: Papillary Thyroid Carcinoma in Denmark, 1943–1968: Cancer 36, 540–552 (1975).PubMedCrossRefGoogle Scholar
  13. Pochin, E.E.: Prospects From the Treatment of Thyroid Carcinoma With Radioiodine. Clin. Radiol. 18, 113–25 (1967).PubMedCrossRefGoogle Scholar
  14. Pochin, E.E.: Radioiodine Therapy of Thyroid Cancer. Semin. Nucl. Med. 1, 503–515 (1971).PubMedCrossRefGoogle Scholar
  15. Rall, J.E., Alpers, J.B., Lewallen, C.G., Sonenberg, M., Berman, M., Rawson, R.W.: Radiation Pneumonitis and Fibrosis: A complication of Radioiodine Treatment of pulmonary metastases from Cancer of the Thyroid. J. clin. Endocr. 17, 1263–1276 (1957).PubMedCrossRefGoogle Scholar
  16. Rawson, R.W., Rall, J.E., Robbins, J.: Uses and Misuses of Radioactive Iodine in Treatment of Cancer of Thyroid. Arch. intern. Med. 92, 299–307 (1953).CrossRefGoogle Scholar
  17. Russell, W.O., Ibanez, M.L., Clark, R.L., White, E.C.: Thyroid Carcinoma: Classification, Intraglandular Dissemination, and Clinicopathological Study Based upon Whole Organ Sections of 80 Glands. Cancer 16, 1425–1460 (1963).PubMedCrossRefGoogle Scholar
  18. Sampson, R.J., Oka, H., Key, C.R., Buncher, C.R., Itjima, S.: Metastases From Occult Thyroid Carcinoma. Cancer 25, 803–811 (1970).PubMedCrossRefGoogle Scholar
  19. Sampson, R.J., Woolner, L.B., Bahn, R.C., Kurland, L.T.: Occult Thyroid Carcinoma in Olmstead County, Minnesota: Prevalence at Autopsy Compared With That in Hiroshima and Nagasaki, Japan. Cancer. 34, 2072–2076 (1974).PubMedCrossRefGoogle Scholar
  20. Scott, J.S., Halnan, K.E., Shimmins, J., Kostaki, P., Mckenzie, H.: Measurement of Dose to Thyroid Carcinoma Metastases from Radio-iodine Therapy. Brit. J. Radiol. 43, 256–262 (1970).PubMedCrossRefGoogle Scholar
  21. Stanbury, J.B., Degroot, L.J.: Methods in Cancer Research, Busch, H. (ed.) New York: Academic Press (1973), 129–159.Google Scholar
  22. Tollefsen, H.R., Shah, J.P., Huvos, A.G.: Follicular Carcinoma of the Thyroid. Amer. J. Surg. 126, 523–528 (1973).PubMedCrossRefGoogle Scholar
  23. Varma, V.M., Beierwaltes, W.H., Nofal, M.M., Nishiyama, R.H. and Copp, J.E.: Treatment of Thyroid Cancer. J. Amer. med. Ass. 214, 1437–42 (1970).CrossRefGoogle Scholar
  24. Woolner, L.B., Beahrs, O.H., Black, B.M., Mcconahey, W.M., Keating, F.R.: Classification and Prognosis of Thyroid Carcinoma. Amer. J. Surg. 102, 354–387 (1961).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • David V. Becker

There are no affiliations available

Personalised recommendations